A study of Tendoncel (Platelet lysate based cell therapy) for the treatment of chronic grade 3 lateral epicondylitis, (severe) tendon injury.

Trial Profile

A study of Tendoncel (Platelet lysate based cell therapy) for the treatment of chronic grade 3 lateral epicondylitis, (severe) tendon injury.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Platelet-lysate-based-cell-therapy-Celixir (Primary)
  • Indications Tennis elbow
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 New trial record
    • 30 Jun 2015 Accordign to the Celixir media release, the endpoints, Improvement in tendon injury, assessed with DASH (Disabilities of the Arm, Shoulder and Hand) PRTEE (Patient-Rated Tennis Elbow Evaluation) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top